ClinicalTrials.gg
CompletedNCT04008706ASSUREUpdated Sep 1, 2026Results posted

Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

A Phase 3 interventional study of Acalabrutinib in Chronic Lymphocytic Leukemia, sponsored by AstraZeneca. Completed at 108 sites in 17 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
552
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
3rd of 39
552 · median 61
Started
2019
with 3 others
Phase 3
9 of 39
1 open now
Registered
15th of 39
by date
Lead sponsor
7 of 39
AstraZeneca

Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 3rd largest by enrollment, is one of 4 that started in 2019, is one of 9 in phase 3, and was the 15th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This is a global, Phase IIIb, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: treatment-naive (TN), relapsed/refractory (R/R), and prior ibrutinib therapy. For this study, participants in the UK will be enrolled ONLY into the R/R cohort or the prior ibrutinib cohort. Participants in the US will be enrolled ONLY into the TN or R/R cohort. Participants will remain on study intervention until completion of 48 cycles (28 days per cycle), or until study intervention discontinuation due to, for example disease progression, or toxicity, withdrawal of consent, loss to follow-up, death, or study termination by the sponsor whichever occurs first. The duration of the study will be approximately 72 months from the first participant enrolled. This duration includes an estimated 24-month recruitment time and an assumed 48 cycles of study intervention (28 days per cycle); additional study time will be accrued during the Disease Follow up period for those participants remaining on study intervention after completion of 48 cycles prior to the final data cutoff (DCO) (the amount of time will vary by participant).

Read the detailed description

This is a Global, Phase IIIb, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg bid in approximately 540 participants with CLL. Participants will be enrolled into one of the 3 following cohorts:

  • Treatment-naive (TN): participants who have had no prior treatment for CLL and who have either a score > 6 on the cumulative illness rating scale and/or have a creatinine clearance of 30 to 69 mL/min using the Cockcroft-Gault equation (minimum of 300 participants). This cohort will not be enrolled in the UK.
  • Relapsed/refractory (R/R): participants who have received prior treatment for CLL and who have either relapsed or refractory CLL (approximately 200 participants).
  • Prior ibrutinib therapy cohort: participants who have received prior ibrutinib for CLL and who discontinued the medication for any reason prior to disease progression (up to 40 participants). This cohort will not be enrolled in the US.

Overall response and progression assessments will be conducted by the investigator in accordance with the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria. Overall response assessments will be based on physical examinations, recording of symptoms, radiologic evaluations, and hematologic evaluations.

Treatment period consists of 48 cycles [each cycle is 28 days). Study medication (acalabrutinib 100 mg bid) will be administered until disease progression, toxicity requiring discontinuation, completion of 48 cycles of study medication, withdrawal of consent, loss to follow-up, death, or study termination by the sponsor, whichever comes first.

48 Cycles: From Cycle 1 to Cycle 6, in-clinic visits will occur every cycle and during each visit, in-clinic assessments will be carried out. From Cycle 7 to Cycle 12, in-clinic visits will occur every 3 cycles and during each visit, in-clinic assessments will be carried out. From Cycle 13 to Cycle 48, in-clinic visits will occur every 3 cycles and in-clinic assessments will be carried out every 6 cycles.

Safety follow up visits will occur approximately 30 days from the last dose of study treatment.

If a participant continues to derive benefit from treatment at the end of 48 cycles prior to the final DCO, they will continue to be provided with study intervention and will be followed in the Disease Follow-up period every 24 weeks (q24w) until study intervention discontinuation due to, for example, disease progression or toxicity, withdrawal of consent, loss to follow-up, death, or study termination by the sponsor, whichever occurs first. Alternatively, at the end of 48 cycles, a participant can decide to switch to commercial off-study acalabrutinib, if available and permitted by local regulations. Post final DCO, 2 options will be considered: participants may be transitioned to another study or may shift to a commercial supply of acalabrutinib/off-study acalabrutinib as permitted by local regulations. Participants who switch to off-study acalabrutinib will be considered as having completed the study and therefore will not have any additional study assessments, including the safety follow-up visit and disease Follow-up period.

The duration of the study will be approximately 72 months from the first participant enrolled. This duration includes an estimated 24-month recruitment time and an assumed 48 cycles of study intervention (28 days per cycle); additional study time will be accrued during the Follow-up period for those participants remaining on study intervention after completion of 48 cycles prior to the final DCO (the amount of time will vary by participant).

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • Chronic lymphocytic leukemia
  • Acalabrutinib
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women ≥18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place)
  2. Diagnosis of CLL that meets all published diagnostic criteria (Hallek et al. 2018):

    1. Monoclonal B-cells (either kappa or lambda light chain restricted) that are clonally co-expressing ≥1 B-cell marker (CD19, CD20, and CD23) and CD5 during screening
    2. Prolymphocytes may comprise \<55% of blood lymphocytes during screening
    3. Presence of ≥5 × 10\^9 B lymphocytes/L (5000/μL) in the peripheral blood (at any point since the initial diagnosis)
  3. Active disease per at least 1 of the following iwCLL 2018 criteria

    1. Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia ( \<10 g/dL) and/or thrombocytopenia ( \<100,000/μL).
    2. Massive (i.e., ≥6 cm below the left costal margin), progressive, or symptomatic splenomegaly.
    3. Massive nodes (i.e., ≥10 cm in the longest diameter), progressive, or symptomatic lymphadenopathy
    4. Progressive lymphocytosis with an increase of >50% over a 2-month period or a lymphocyte doubling time (LDT) of \<6 months. LDT may be obtained by linear regression extrapolation of absolute lymphocyte count obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In participants with initial blood lymphocyte counts of \<30x10\^9/L (30,000/μL), LDT should not be used as a single parameter to define indication for treatment. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g., infections) should be excluded.
    5. anemia and/or thrombocytopenia that is poorly responsive to standard therapy
    6. B-symptoms documented in the participant's chart with supportive objective measures, as appropriate, defined as ≥1 of the following disease-related symptoms or signs: o- Unintentional weight loss ≥10% within the previous 6 months before screening o- Significant fatigue ( [ECOG] performance status ≥2; inability to work or perform usual activities) o- Fevers higher than 100.5°F or 38.0°C for ≥2 weeks o- Night sweats for ≥1 month before screening without evidence of infection
  4. Must meet one of the following criteria:

    a. Have received no prior therapy for treatment of CLL and meets one of the following criteria (for this study, participants in the UK will be enrolled ONLY in the R/R or the prior ibrutinib cohort): i. A score of >6 on the Cumulative Illness Rating Scale (CIRS) ii. of 30 to 69 mL/min using the Cockcroft-Gault equation b. Have previously received therapy for CLL and have either or relapsed CLL c. Have received prior ibrutinib therapy (i.e., defined as a participant who discontinued a ibrutinib for any reason prior to disease progression) for CLL (participants in the US will not be enrolled into the prior ibrutinib therapy cohort)

  5. ECOG performance status of ≤2
  6. Female participants of (i.e., not surgically sterile or ) who are sexually active with a non-sterilized male partner must use ≥1 highly effective method of from the time of screening and must agree to continue using such precautions for 2 days after the last dose of study intervention. Contraception measures and restrictions on sperm donation are not required for male participants.
  7. Fluorescence in situ hybridization (FISH) for which the next-generation sequencing (NGS) method is preferred) within 60 days during screening up to before the first dose reflecting the presence or absence of del(17p), del(13q), del(11q), and trisomy of chromosome 12 along with the percentage of cells with the deletion, along with TP53 sequencing. Participants must also have molecular analysis to detect IGHV mutation status (NGS is the preferred method) at screening if not done at any time point before that since diagnosis.
  8. Each participant (or legally authorized representative if allowed per local regulations) must be willing and able to adhere to the study visit schedule, understand and comply with other protocol requirements, and provide written and authorization to use protected health information.

Exclusion criteria

Exclusion Criteria:

  1. Participants who have had disease progression while on a BTKi for any malignant or nonmalignant condition
  2. Prior (other than CLL), except for adequately treated basal cell or squamous cell skin cancer, in situ cancer, early stage prostate cancer, or other cancer from which the participant has been disease-free for ≥2 years
  3. History of confirmed progressive multifocal leukoencephalopathy
  4. Significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months before screening, or any Class 3 or 4 cardiac disease as defined by the Functional Classification, or interval using Fridericia's formula (QTcF) >480 msec at screening. Note: Participants with rate-controlled, asymptomatic atrial fibrillation are allowed to enroll in the study (For prior ibrutinib therapy cohort only, except in Finland and the Republic of South Korea, where this is applicable to all 3 cohorts; also, the prior ibrutinib therapy cohort will not be enrolled in the US).
  5. Malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
  6. Evidence of active Richter's transformation. If Richter's transformation is suspected (i.e., lactate dehydrogenase [LDH] increased, asymmetric fast lymph node growth or clinical suspicion), it should be ruled out with positron emission tomographycomputed tomography (PET-CT) and/or according to guidelines.
  7. Central nervous system (CNS) involvement by CLL.
  8. Known history of , serologic status reflecting active virus or virus infection, any uncontrolled active systemic infection along with participants who are on ongoing anti-infective treatment and participants who have received vaccination with a within 4 weeks before the first dose of study intervention.

    1. Participants who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antibody (anti-HBs) negative will need to have a negative hepatitis B virus PCR result before enrollment. Those who are hepatitis B surface antigen (HBsAg) positive or hepatitis B virus PCR positive will be excluded.
    2. Participants who are hepatitis C virus antibody positive will need to have a negative hepatitis C virus PCR result before enroll.lment. Those who are hepatitis C virus PCR positive will be excluded
  9. Uncontrolled hemolytic anemia or idiopathic thrombocytopenic purpura defined as declining or count secondary to autoimmune destruction within the screening period or requirement for high doses of (>20 mg daily of prednisone or equivalent for longer than 2 weeks).
  10. History of stroke or intracranial hemorrhage within 6 months before the first dose of study intervention.
  11. History of bleeding diathesis (e.g., hemophilia or von Willebrand disease)
  12. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening.
  13. Major surgical procedure within 4 weeks before first dose of study intervention. Note: Participants who have had major surgery must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study intervention.
  14. Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Participants receiving proton-pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment in this study.
  15. All participants requiring or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within 7 days before first dose of study intervention. Based on the known metabolic/transport pathways involved in the disposition of acalabrutinib and the commonly known novel oral anticoagulants (eg, apixaban, rivaroxaban, and edoxaban), no interaction is expected following coadministration of these agents.
  16. (ANC) \<0.50 x 10\^9/L or platelet count \<30 x 10\^9/L, unless proven due to CLL and raised above the limits by granulocyte colony-stimulating factor (G-CSF) therapy and/or pooled platelet transfusion
  17. Total >3.0x (ULN); or or alanine aminotransferase >3.0x ULN. Exception will be for Gilbert syndrome; if an investigator feels that a participant's total bilirubin is elevated secondary to Gilbert's, the participant must have a documented unconjugated bilirubin being >80% of the total bilirubin number. The investigator must also document that hemolysis has been ruled out along with (near)-normal lactate dehydrogenase and haptoglobin
  18. Estimated of \<30 mL/min, calculated using the formula of Cockcroft and Gault or by direct assessment (i.e., creatinine clearance or ethylene diamine tetra-acetic acid (EDTA) clearance measurement)
  19. Breastfeeding or pregnant
  20. Received any chemotherapy, external beam radiation, drug, or any other anti-CLL therapy within 30 days before first dose of study intervention
  21. Concurrent participation in another therapeutic clinical study
  22. History of or ongoing interstitial lung disease
  23. Requiring long-term (> 1 week) treatment with a strong cytochrome inhibitor/inducer. In addition, the use of strong or moderate CYP3A inhibitors or inducers within 7 days of the first dose of study intervention is prohibited.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
552 participants (actual)

Study arms

  • Experimental
    Acalabrutinib

    Participants will be enrolled into 3 cohorts. In the treatment-naive cohort, a minimum of 300 participants with treatment-naïve chronic lymphocytic leukemia will be enrolled. In the relapsed/refractory cohort, approximately 200 participants with relapsed/refractory chronic lymphocytic leukemia will be enrolled. In the prior ibrutinib cohort, approximately 40 participants with Prior ibrutinib therapy will be enrolled.

    Drug: Acalabrutinib

Interventions

  • Acalabrutinib will be administered as one 100 mg capsule taken orally, twice daily with 8 ounces (approximately 240 mL) of water.

    Also known as: ACP-196

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    The safety and tolerability of acalabrutinib monotherapy were evaluated in participants with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia. Treatment-emergent AEs (TEAEs) were defined as AEs that started after first dose of acalabrutinib or which started prior to first dose of acalabrutinib but worsened following first dose of acalabrutinib, and where the start date of worsening was also no later than 30 days after the date of last dose of acalabrutinib or the first date starting new anticancer therapy, whichever was earlier. Adverse events of special interest (AESI) were defined as ventricular arrhythmias. Events of clinical interest (ECI) were defined as cardiac events, hepatotoxicity, hypertension, infections, interstitial lung disease/pneumonitis, hemorrhage (major hemorrhage), cytopenias (anemia, leukopenia, thrombocytopenia), second primary malignancies, and tumor lysis syndrome. Common Terminology Criteria for Adverse Events = CTCAE

    Time frame: Up to safety follow-up period (about 30 days from last dose) (approximately 74 months)

Secondary outcomes

  1. Overall Response (OR)

    The investigator-assessed OR was evaluated in participants receiving acalabrutinib monotherapy. OR was defined as a participant's best OR to the treatment and the overall response rate (ORR) has been reported for the proportion of participants who were considered responders. A participant was considered a responder if s(he) achieved complete response (CR), complete response with incomplete marrow recovery (CRi), or partial response (PR), according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria.

    Time frame: 1 year after initial dose of study intervention

  2. Duration of Response (DOR)

    The investigator-assessed DOR was evaluated in participants receiving acalabrutinib monotherapy. DOR was defined as the time from the first OR of CR, CRi, or PR to the time of documented disease progression or death due to any cause, whichever occurred first.

    Time frame: The time from the first objective response to the time of documented disease progression or death due to any cause, whichever occurred first within the time period to complete up to 48 cycles of treatment (each cycle was 28 days) (approximately 74 months)

  3. Progression-free Survival (PFS)

    The investigator-assessed PFS was evaluated in participants receiving acalabrutinib monotherapy. PFS was defined as the interval from the start of study intervention to the earlier of the first documentation of disease progression or death from any cause.

    Time frame: From the start of study intervention to completion of 48 cycles (each cycle was 28 days) or the earlier of the first documentation of disease progression or death from any cause (approximately 74 months)

07

Results

Posted Sep 1, 2026

Participant flow

The study was conducted from 17 September 2019 (first participant enrolled) to 04 November 2025 (last participant last visit) at 108 study centers across 17 countries.

Participant flow — Overall Study
MilestoneAcalabrutinib Treatment-naïve (TN) CohortAcalabrutinib Relapsed/Refractory (R/R) CohortAcalabrutinib Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Therapy Cohort
Started31020240
Completed19910615
Not completed1119625
Withdrew: Participant decision1543
Withdrew: Adverse event55599
Withdrew: Condition under investigation worsened14269
Withdrew: Development of study specific discontinuation criteria211
Withdrew: Investigator decision800
Withdrew: Death220
Withdrew: Consent withdrawal310
Withdrew: Other1223
Withdrew: Missing010

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

The safety and tolerability of acalabrutinib monotherapy were evaluated in participants with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia. Treatment-emergent AEs (TEAEs) were defined as AEs that started after first dose of acalabrutinib or which started prior to first dose of acalabrutinib but worsened following first dose of acalabrutinib, and where the start date of worsening was also no later than 30 days after the date of last dose of acalabrutinib or the first date starting new anticancer therapy, whichever was earlier. Adverse events of special interest (AESI) were defined as ventricular arrhythmias. Events of clinical interest (ECI) were defined as cardiac events, hepatotoxicity, hypertension, infections, interstitial lung disease/pneumonitis, hemorrhage (major hemorrhage), cytopenias (anemia, leukopenia, thrombocytopenia), second primary malignancies, and tumor lysis syndrome. Common Terminology Criteria for Adverse Events = CTCAE

Time frame:
Up to safety follow-up period (about 30 days from last dose) (approximately 74 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsAcalabrutinib TN CohortAcalabrutinib R/R CohortAcalabrutinib Prior BTKi Therapy Cohort
Any TEAE30620040
Any TEAE, possibly related to acalabrutinib25314938
Any TEAE with CTCAE Grade 3 or higher19314022
Any TEAE with CTCAE Grade 3 or higher, possibly related to acalabrutinib855911
Any Serious TEAE15211812
Any Serious TEAE, possibly related to acalabrutinib41313
Any TEAE with outcome death26365
Any TEAE with outcome death, possibly related to acalabrutinib321
Any TEAE leading to discontinuation of acalabrutinib596411
Any TEAE leading to discontinuation of acalabrutinib, possibly related to acalabrutinib23155
Any AESI301
Any ECI28419238
SecondaryOverall Response (OR)

The investigator-assessed OR was evaluated in participants receiving acalabrutinib monotherapy. OR was defined as a participant's best OR to the treatment and the overall response rate (ORR) has been reported for the proportion of participants who were considered responders. A participant was considered a responder if s(he) achieved complete response (CR), complete response with incomplete marrow recovery (CRi), or partial response (PR), according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria.

Time frame:
1 year after initial dose of study intervention
Reported as:
Number · Percentage of participants
Overall Response (OR)
Percentage of participantsAcalabrutinib TN CohortAcalabrutinib R/R CohortAcalabrutinib Prior BTKi Therapy Cohort
Overall Response (OR)82.3 (77.54 to 86.35)75.7 (69.23 to 81.48)55.0 (38.49 to 70.74)
SecondaryDuration of Response (DOR)

The investigator-assessed DOR was evaluated in participants receiving acalabrutinib monotherapy. DOR was defined as the time from the first OR of CR, CRi, or PR to the time of documented disease progression or death due to any cause, whichever occurred first.

Time frame:
The time from the first objective response to the time of documented disease progression or death due to any cause, whichever occurred first within the time period to complete up to 48 cycles of treatment (each cycle was 28 days) (approximately 74 months)
Reported as:
Median · Months
Duration of Response (DOR)
MonthsAcalabrutinib TN CohortAcalabrutinib R/R CohortAcalabrutinib Prior BTKi Therapy Cohort
Duration of Response (DOR)NA (NA to NA)47.2 (46.0 to 51.0)33.3 (23.2 to NA)
SecondaryProgression-free Survival (PFS)

The investigator-assessed PFS was evaluated in participants receiving acalabrutinib monotherapy. PFS was defined as the interval from the start of study intervention to the earlier of the first documentation of disease progression or death from any cause.

Time frame:
From the start of study intervention to completion of 48 cycles (each cycle was 28 days) or the earlier of the first documentation of disease progression or death from any cause (approximately 74 months)
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsAcalabrutinib TN CohortAcalabrutinib R/R CohortAcalabrutinib Prior BTKi Therapy Cohort
Progression-free Survival (PFS)NA (NA to NA)57.3 (51.71 to 60.42)44.4 (29.67 to NA)

Adverse events

Collected over Up to safety follow-up period (about 30 days from last dose) (approximately 74 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Acalabrutinib TN Cohort29/310 (9.4%)152/310 (49%)294/310 (94.8%)
Acalabrutinib R/R Cohort42/202 (20.8%)118/202 (58.4%)180/202 (89.1%)
Acalabrutinib Prior BTKi Therapy Cohort5/40 (12.5%)12/40 (30%)39/40 (97.5%)
Most frequent serious events
Showing 10 of 246
Most frequent serious events
EventAcalabrutinib TN CohortAcalabrutinib R/R CohortAcalabrutinib Prior BTKi Therapy Cohort
COVID-19Infections and infestations34/31036/2021/40
PneumoniaInfections and infestations18/31022/2025/40
COVID-19 pneumoniaInfections and infestations9/31020/2020/40
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders4/3100/2022/40
Post-acute COVID-19 syndromeInfections and infestations0/3100/2021/40
Respiratory tract infection viralInfections and infestations0/3100/2021/40
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3101/2021/40
AnaemiaBlood and lymphatic system disorders4/3101/2021/40
Tumour lysis syndromeMetabolism and nutrition disorders0/3100/2021/40
Intracranial haematomaNervous system disorders0/3100/2021/40
Most frequent other events
Showing 10 of 96
Most frequent other events
EventAcalabrutinib TN CohortAcalabrutinib R/R CohortAcalabrutinib Prior BTKi Therapy Cohort
HeadacheNervous system disorders134/31078/20228/40
COVID-19Infections and infestations117/31076/20213/40
DiarrhoeaGastrointestinal disorders107/31060/20213/40
ArthralgiaMusculoskeletal and connective tissue disorders79/31032/20213/40
ContusionInjury, poisoning and procedural complications90/31043/2029/40
FatigueGeneral disorders67/31025/20210/40
Influenza like illnessGeneral disorders17/3109/2029/40
NauseaGastrointestinal disorders63/31037/2028/40
ConstipationGastrointestinal disorders57/31015/2022/40
AnaemiaBlood and lymphatic system disorders43/31037/2027/40

Baseline characteristics

Safety analysis set included participants who had received ≥ 1 dose (partial or in full) of study intervention.

Age, Continuous
Age, Continuous(Years)Acalabrutinib TN CohortAcalabrutinib R/R CohortAcalabrutinib Prior BTKi Therapy CohortTotal
Mean69.6 ± 9.4767.2 ± 9.9968.2 ± 12.1168.6 ± 9.92
Sex: Female, Male
Sex: Female, Male(Participants)Acalabrutinib TN CohortAcalabrutinib R/R CohortAcalabrutinib Prior BTKi Therapy CohortTotal
Female1128122215
Male19812118337
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Acalabrutinib TN CohortAcalabrutinib R/R CohortAcalabrutinib Prior BTKi Therapy CohortTotal
Hispanic or Latino2228656
Not Hispanic or Latino24915930438
Unknown or Not Reported3915458
08

Study locations

108 sites
  • Research Site
    Chandler, Arizona 85224, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Redlands, California 92373, United States
  • Research Site
    Whittier, California 90603, United States
  • Research Site
    Fort Myers, Florida 33908, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    St. Petersburg, Florida 33705, United States
  • Research Site
    Marietta, Georgia 30060, United States
  • Research Site
    Normal, Illinois 61761, United States
  • Research Site
    Peoria, Illinois 61615, United States
  • Research Site
    Fort Wayne, Indiana 46845, United States
  • Research Site
    Indianapolis, Indiana 46260, United States
  • Research Site
    Shreveport, Louisiana 71105, United States
  • Research Site
    Saint Cloud, Minnesota 56303, United States
  • Research Site
    Kansas City, Missouri 64132, United States
  • Research Site
    Bethlehem, Pennsylvania 18015, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Dallas, Texas 75235, United States
  • Research Site
    Adelaide, 5000, Australia
  • Research Site
    Bedford Park, 5042, Australia
  • Research Site
    Clayton, 3168, Australia
  • Research Site
    Fitzroy, 3065, Australia
  • Research Site
    Nedlands, 6009, Australia
  • Research Site
    South Brisbane, 4101, Australia
  • Research Site
    Belo Horizonte, 30130-100, Brazil
  • Research Site
    Curitiba, 81520-060, Brazil
  • Research Site
    Goiânia, 74605-020, Brazil
  • Research Site
    Porto Alegre, 90035-003, Brazil
  • Research Site
    Porto Alegre, 90110-270, Brazil
  • Research Site
    Ribeirão Preto, 14048-900, Brazil
  • Research Site
    São Paulo, 01236-030, Brazil
  • Research Site
    São Paulo, 01323-900, Brazil
  • Research Site
    Calgary, Alberta T2N 4N2, Canada
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Victoria, British Columbia V8R 6V5, Canada
  • Research Site
    Winnipeg, Manitoba R3E 0V9, Canada
  • Research Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Research Site
    Brampton, Ontario L6R 3J7, Canada
  • Research Site
    Newmarket, Ontario L3Y 2P9, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Aalborg, 9100, Denmark
  • Research Site
    Aarhus, 8200, Denmark
  • Research Site
    Herlev, 2730, Denmark
  • Research Site
    København Ø, 2100, Denmark
  • Research Site
    Odense, 5000, Denmark
  • Research Site
    Roskilde, 4000, Denmark
  • Research Site
    Hus, 00029, Finland
  • Research Site
    Kuopio, 70210, Finland
  • Research Site
    Tampere, 33521, Finland
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Brest, 29609, France
  • Research Site
    Limoges, 87042, France
  • Research Site
    Reims, 51092, France
  • Research Site
    Tours, 37000, France
  • Research Site
    Vandœuvre-lès-Nancy, 54511, France
  • Research Site
    Bayern, 63739, Germany
  • Research Site
    Essen, 45147, Germany
  • Research Site
    Homburg, 66421, Germany
  • Research Site
    Porta Westfalica, 32457, Germany
  • Research Site
    Schwäbisch Hall, 74523, Germany
  • Research Site
    Catanzaro, 88100, Italy
  • Research Site
    Milan, 20122, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Siena, 53100, Italy
  • Research Site
    Arnhem, 6815 AD, Netherlands
  • Research Site
    Dordrecht, 3318 AT, Netherlands
  • Research Site
    Utrecht, 3584 CX, Netherlands
  • Research Site
    Bergen, 5053, Norway
  • Research Site
    Oslo, 1478, Norway
  • Research Site
    Trondheim, 7006, Norway
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Moscow, 125167, Russia
  • Research Site
    Moscow, 125284, Russia
  • Research Site
    Nizhny Novgorod, 603126, Russia
  • Research Site
    Petrozavodsk, 185019, Russia
  • Research Site
    Saint Petersburg, 191024, Russia
  • Research Site
    Saint Petersburg, 194291, Russia
  • Research Site
    Saint Petersburg, 197022, Russia
  • Research Site
    Saint Petersburg, 197110, Russia
  • Research Site
    Saint Petersburg, 197341, Russia
  • Research Site
    Smolensk, 214015, Russia
  • Research Site
    Smolensk, 214031, Russia
  • Research Site
    Syktyvkar, 167904, Russia
  • Research Site
    Busan, 49241, South Korea
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 06591, South Korea
  • Research Site
    Seoul, 135-710, South Korea
  • Research Site
    Ulsan, 44033, South Korea
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Madrid, 28006, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Marbella, 29603, Spain
  • Research Site
    Ourense, 32005, Spain
  • Research Site
    Oviedo, 33011, Spain
  • Research Site
    Vitoria-Gasteiz, 01009, Spain
  • Research Site
    Zaragoza, 50009, Spain
  • Research Site
    Luleå, 97180, Sweden

Showing the first 100 of 108 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Nov 2025, 73 months.

Results were first posted in Sep 2026, 9 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 73 months is above that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2019
First posted
Jul 5, 2019
StartActual
Sep 17, 2019
Primary completionActual
Nov 4, 2025
CompletionActual
Nov 4, 2025
Results first posted
Sep 1, 2026
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04008706
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jul 5, 2019
Start date
Sep 17, 2019
Primary completion
Nov 4, 2025
Completion
Nov 4, 2025
Results posted
Sep 1, 2026
Last update
Sep 1, 2026

Study contacts

Adel Habib, MD
study director · AstraZeneca
Dr. Carsten Niemann, MD
principal investigator · Rigshospitalet, Denmark

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion